Antilymphoma therapy with a Bcl-6 inhibitor Peter McLaughlin Clinical Trials Report 01 October 2009 Pages: 183 - 184
Chemoimmunotherapy with modified dosing of fludarabine, cyclophosphamide, and rituximab shows significant clinical activity in patients with previously untreated chronic lymphocytic leukemia Nicole LamannaMark A. Weiss Clinical Trials Report 01 October 2009 Pages: 185 - 186
Vaccination strategies in follicular lymphoma Shibichakravarthy KannanSattva S. Neelapu OriginalPaper 01 October 2009 Pages: 189 - 195
The host-tumor interface in B-cell non-Hodgkin lymphoma: A new world to investigate Nicolas RachinelGilles Salles OriginalPaper 01 October 2009 Pages: 196 - 201
Prognostic factors in low-grade non-Hodgkin lymphomas Massimo FedericoStefano MolicaStefano Luminari OriginalPaper 01 October 2009 Pages: 202 - 210
Frontline therapy in mantle cell lymphoma: The role of high-dose therapy and integration of new agents Brad S. Kahl OriginalPaper 01 October 2009 Pages: 213 - 217
Beyond R-CHOP and the IPI in large-cell lymphoma: Molecular markers as an opportunity for stratification Jason R. WestinLuis E. Fayad OriginalPaper 01 October 2009 Pages: 218 - 224
Update on the World Health Organization classification of peripheral T-cell lymphomas Hilary M. O’LearyKerry J. Savage OriginalPaper 01 October 2009 Pages: 227 - 235
Hemopoietic stem cell transplantation in T-cell malignancies: Who, when, and how? Francesco d’AmoreEsa JantunenThomas Relander OriginalPaper 01 October 2009 Pages: 236 - 244
Natural killer-cell neoplasms John P. GreerClaudio A. Mosse OriginalPaper 01 October 2009 Pages: 245 - 252
